期刊文献+

Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease 被引量:10

Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease
下载PDF
导出
摘要 AIM: To shed some light on the relationship between anti-apoptotic serum Bcl-2 concentrations and metabolic status, anthropometric parameters, inflammation indices, and non-alcoholic fatty liver disease severity were investigated in 43 young individuals with fatty liver (FL)and 41 with nonalcoholic steatohepatitis (NASH).METHODS: Circulating levels of Bcl-2 were detected in 84 patients with ultrasono graphic findings of "bright liver" and/or hyper-transaminasemia of unknown origin and/or increase in γ-glutamyl-transpeptidase (γ-GT)strictly in the absence of other acute or chronic liver disease, whose age was not advanced, who gave consent to liver biopsy and were then divided on the basis of the histological results into two groups (43 with FL and 41 with NASH). Twenty lean subjects, apparently healthy and young, were chosen as controls.RESULTS: Serum Bcl-2 concentrations were significantly higher in the FL group than in the NASH group. Insulin resistance and γ-GT activity were significantly higher in NASH subjects. Apoptotic hepatocytes were significantly more numerous in NASH patients. NASH patients presented with larger spleens and augmented C-reactive protein (CRP) concentrations than healthy subjects. Steatosis grade at histology was similar in both NASH and FL populations. The number of apoptotic cells was significantly related to anti-apoptotic Bcl-2 protein values in FL patients. Bcl-2 serum levels positively correlated to body mass index (BMI) values (P ≤ 0.0001) but not to age of the population. Triglycerides/HDL ratio correlated well to waist circumference in males (P = 0.0008).γ-GT activity was associated with homeostatic metabolic assessment (HOMA) (P = 0.0003) and with serum ferritin (P = 0.02). Bcl-2 concentrations were not related to either spleen size or CRP values. NASH patients presented a weak negative correlation between lobular inflammation and Bcl-2 levels. A prediction by low values of serum Bcl-2 towards a greater presence of metaboli-cally unhealthy overweight/obese patients (MUOs) was evidenced. HOMA, BMI and uric acid, in that sequence,best predicted serum Bcl-2 concentrations.CONCLUSION: MUOs could be detected by Bcl-2 levels.By favoring the life span of hepatocytes, and enhancing triglyceride formation, the anti-apoptotic process inhibits free fatty acids toxicity in FL. AIM: To shed some light on the relationship between anti-apoptotic serum Bcl-2 concentrations and metabolic status, anthropometric parameters, inflammation indi- ces, and non-alcoholic fatty liver disease severity were investigated in 43 young individuals with fatty liver (FL) and 41 with nonalcoholic steatohepatitis (NASH). METHODS: Circulating levels of Bcl-2 were detected in 84 patients with ultrasonographic findings of "bright liver" and/or hyper-transaminasemia of unknown origin and/or increase in T-glutamyl-transpeptidase (T-GT) strictly in the absence of other acute or chronic liver disease, whose age was not advanced, who gave consent to liver biopsy and were then divided on the basis of the histological results into two groups (43 with FL and 41 with NASH). Twenty lean subjects, apparently healthy and young, were chosen as controls.RESULTS: Serum Bcl-2 concentrations were significantly higher in the FL group than in the NASH group. Insulin resistance and γ-GT activity were significantly higher in NASH subjects. Apoptotic hepatocytes were significantly more numerous in NASH patients. NASH patients presented with larger spleens and augmented C-reactive protein (CRP) concentrations than healthy subjects. Steatosis grade at histology was similar in both NASH and FL populations. The number of apoptotic cells was significantly related to anti-apoptotic Bcl-2 protein values in FL patients. Bcl-2 serum levels positively correlated to body mass index (BMI) values (P ~ 0.0001) but not to age of the population. Triglycerides/HDL ratio correlated well to waist circumference in males (P = 0.0008). γ-GT activity was associated with homeostatic metabolic assessment (HOMA) (P = 0.0003) and with serum ferritin (P = 0.02). Bcl-2 concentrations were not related to either spleen size or CRP values. NASH patients pre- sented a weak negative correlation between Iobular inflammation and Bcl-2 levels. A prediction by low values of serum Bcl-2 towards a greater presence of metabolically unhealthy overweight/obese patients (MUOs) was evidenced. HOMA, BMI and uric acid, in that sequence, best predicted serum Bcl-2 concentrations. CONCLUSION: IvlUOs could be detected by Bcl-2 levels. By favoring the life span of hepatocytes, and enhancing triglyceride formation, the anti-apoptotic process inhibits free fatty acids toxicity in FL.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第48期5280-5288,共9页 世界胃肠病学杂志(英文版)
关键词 BCL-2 不含酒精的脂肪肝疾病 新陈代谢地不健康的超重 / 肥胖 Bcl-2 Nonalcoholic fatty liver disease Meta-bolically unhealthy overweight/obese
  • 相关文献

参考文献3

二级参考文献38

  • 1SeyedAliGaskari,SamuelSLee.Cardiac and vascular changes in cirrhosis:Pathogenic mechanisms[J].World Journal of Gastroenterology,2006,12(6):837-842. 被引量:33
  • 2[1]Festi D,Colecchia A,Sacco T,Bondi M,Roda E,Marchesini G.Hepatic steatosis in obese patients:clinical aspects and prognostic significance.Obes Rev 2004; 5:27-42
  • 3[2]Browning JD,Horton JD.Molecular mediators of hepatic steatosis and liver injury.J Clin Invest 2004; 114:147-152
  • 4[3]Dam-Larsen S,Franzmann M,Andersen IB,Christoffersen P,Jensen LB,Sorensen TI,Becker U,Bendtsen F.Long term prognosis of fatty liver:risk of chronic liver disease and death.Gut 2004; 53:750-755
  • 5[4]James O,Day C.Non-alcoholic steatohepatitis:another disease of affluence.Lancet 1999; 353:1634 -1636
  • 6[5]Matteoni CA,Younossi ZM,Gramlich T,Boparai N,Liu YC,McCullough AJ.Nonalcoholic fatty liver disease:a spectrum of clinical and pathological severity.Gastroenterology 1999; 116:1413-1419
  • 7[6]Miner JL,Cederberg CA,Nielsen MK,Chen X,Baile CA.Conjugated linoleic acid (CLA),body fat,and apoptosis.Obes Res 2001; 9:129-134
  • 8[7]Angulo P,Keach JC,Batts KP,Lindor KD.Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.Hepatology 1999; 30:1356-1362
  • 9[8]Tsuboyama-Kasaoka N,Takahashi M,Tanemura K,Kim HJ,Tange T,Okuyama H,Kasai M,Ikemoto S,Ezaki O.Conjugated linoleic acid supplementation reduces adipose tissue by apoptosis and develops lipodystrophy in mice.Diabetes 2000;49:1534-1542
  • 10[9]Yahagi N,Shimano H,Matsuzaka T,Sekiya M,Najima Y,Okazaki S,Okazaki H,Tamura Y,Iizuka Y,Inoue N,Nakagawa Y,Takeuchi Y,Ohashi K,Harada K,Gotoda T,Nagai R,Kadowaki T,Ishibashi S,Osuga J,Yamada N.p53involvement in the pathogenesis of fatty liver disease.J Biol Chem 2004; 279:20571-20575

共引文献70

同被引文献156

引证文献10

二级引证文献207

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部